» Articles » PMID: 23273871

The Rasch-built Pompe-specific Activity (R-PAct) Scale

Overview
Specialty Neurology
Date 2013 Jan 1
PMID 23273871
Citations 24
Authors
Affiliations
Soon will be listed here.
Abstract

We constructed a patient-based interval scale using Rasch analysis, specifically suited to quantify the effects of Pompe disease on patient's ability to carry out daily life activities and their social participation: Rasch-built Pompe-specific Activity scale. Between July 2005 and April 2011, 186 patients aged 16 or older, participated to develop this scale. External construct validity was determined through correlations with the MRC sumscore and Rotterdam Handicap Scale. Furthermore, test-retest reliability was determined in a subgroup of 44 patients. Finally, individual person-level responsiveness was used to determine the proportion of patients demonstrating significant improvement or deterioration during their natural disease course, or during treatment with enzyme replacement therapy. Of the original 49 items, 31 were removed after investigation of model fit, internal reliability, threshold examination, item bias, and local dependency. The remaining 18 items were ordered on a linearly weighted scale and demonstrated good discriminative ability (Person Separation Index 0.96), external construct validity (intraclass correlation coefficient (ICC) for MRC sumscore 0.82, and for the Rotterdam handicap scale 0.86), reliability of person's location (ability comparison: ICC 0.95), and responsiveness. We therefore conclude that the R-PAct scale enables us to accurately detect limitations in activities and social participation throughout the entire disease spectrum in patients with Pompe disease.

Citing Articles

Switching treatment to cipaglucosidase alfa plus miglustat positively affects patient-reported outcome measures in patients with late-onset Pompe disease.

Kishnani P, Byrne B, Claeys K, Diaz-Manera J, Dimachkie M, Kushlaf H J Patient Rep Outcomes. 2024; 8(1):132.

PMID: 39535661 PMC: 11561219. DOI: 10.1186/s41687-024-00805-w.


Living with Pompe disease: results from a qualitative interview study with children and adolescents and their caregivers.

Truninger M, Werner H, Landolt M, Hahn A, Hennermann J, Lagler F Orphanet J Rare Dis. 2024; 19(1):358.

PMID: 39342352 PMC: 11438293. DOI: 10.1186/s13023-024-03368-7.


Non-invasive optoacoustic imaging of glycogen-storage and muscle degeneration in late-onset Pompe disease.

Tan L, Zschuntzsch J, Meyer S, Stobbe A, Bruex H, Regensburger A Nat Commun. 2024; 15(1):7843.

PMID: 39245687 PMC: 11381542. DOI: 10.1038/s41467-024-52143-6.


Improving outcome measures in late onset Pompe disease: Modified Rasch-Built Pompe-Specific Activity scale.

van Kooten H, Horton M, Wenninger S, Babacic H, Schoser B, Lefeuvre C Eur J Neurol. 2024; 31(12):e16397.

PMID: 39205420 PMC: 11554865. DOI: 10.1111/ene.16397.


Bulbar muscle impairment in patients with late onset Pompe disease: Insight from the French Pompe registry.

Retailleau E, Lefeuvre C, Antonio M, Bouhour F, Tard C, Salort-Campana E Eur J Neurol. 2024; 31(10):e16428.

PMID: 39109844 PMC: 11414798. DOI: 10.1111/ene.16428.